Q-omics provides the consensus-scored MIR190B profile across patient tissues and cancer cell-line models. MIR190B expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR190B is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR190B RNA expression shows 6,407 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight HNSC, BRCA, and COAD as cancer lineages where MIR190B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR190B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR190B survival associations across molecular data types. MIR190B RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR190B RNA expression–survival associations across cancer types. High MIR190B expression shows unfavorable associations in HNSC, ACC, THCA, BLCA, LUSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR190B RNA expression.
This table summarizes MIR190B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR190B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR190B shows higher tumor expression in BRCA. The BRCA box plot shows higher MIR190B RNA expression in tumor versus normal tissue (log2 FC = +0.142, t-test p = .009).
This table shows molecular features associated with MIR190B in patient tissues and cancer cell lines. In patient samples, MIR190B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
